Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer - Authors' reply

Affiliations

¹ Department of Radiation Oncology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China. Electronic address: zhuxiaofei_zxf@163.com.
² Department of Radiation Oncology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.

Comment

Xiaofei Zhu et al. Lancet Oncol. 2021 Oct.

. 2021 Oct;22(10):e424.

doi: 10.1016/S1470-2045(21)00529-5.

¹ Department of Radiation Oncology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China. Electronic address: zhuxiaofei_zxf@163.com.
² Department of Radiation Oncology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.

No abstract available

Conflict of interest statement

We declare no competing interests.

Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu X, Cao Y, Liu W, Ju X, Zhao X, Jiang L, Ye Y, Jin G, Zhang H. Zhu X, et al. Lancet Oncol. 2021 Aug;22(8):1093-1102. doi: 10.1016/S1470-2045(21)00286-2. Epub 2021 Jul 5. Lancet Oncol. 2021. Retraction in: Lancet Oncol. 2022 Mar;23(3):330. doi: 10.1016/S1470-2045(22)00064-X. PMID: 34237249 Retracted. Clinical Trial.
Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer.
Okano N, Mizutani T, Nagashima F, Furuse J. Okano N, et al. Lancet Oncol. 2021 Oct;22(10):e423. doi: 10.1016/S1470-2045(21)00489-7. Lancet Oncol. 2021. PMID: 34592184 No abstract available.